<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116414</article-id><article-id pub-id-type="publisher-id">ACM-43449</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_68896748.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  重组人血小板生成素在造血干细胞移植中应用的研究进展
  Progress in the Application of Recombinant Human Thrombopoietin in Hematopoietic Stem Cell
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>玥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>彦丽</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>丽</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>接</surname><given-names>贵涛</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>潍坊医学院，山东 潍坊</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>临沂市中心医院血液科，山东 临沂</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2851</fpage><lpage>2856</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  造血干细胞移植相关血小板减少是移植后常见的并发症之一，其病因复杂，尚无明确的治疗方法。重组人血小板生成素在移植前的动员阶段和移植后期均发挥作用，降低移植相关血小板减少发生的同时，减少了血小板的输注，表现出良好的安全性。本文将对重组人血小板生成素在移植前后的运用作一综述。
   Transplant-associated thrombocytopenia is one of the common complications after transplantation, which has complicated etiology and doesn't have definite treatment. Recombinant human thrombopoietin plays an important role in both the mobilization stage before transplantation and the post-transplantation stage, improving the occurrence of transplant-related thrombocytopenia and reducing the transfusion of platelets. At the same time, it shows good safety. The application of recombinant human thrombopoietin before and after transplantation is reviewed in this paper.
 
</p></abstract><kwd-group><kwd>重组人血小板生成素，移植相关血小板减少，造血干细胞移植, Recombinant Human Thrombopoietin</kwd><kwd> Transplant-Associated Thrombocytopenia</kwd><kwd> Hemopoietic Stem Cell Transplantation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>造血干细胞移植相关血小板减少是移植后常见的并发症之一，其病因复杂，尚无明确的治疗方法。重组人血小板生成素在移植前的动员阶段和移植后期均发挥作用，降低移植相关血小板减少发生的同时，减少了血小板的输注，表现出良好的安全性。本文将对重组人血小板生成素在移植前后的运用作一综述。</p></sec><sec id="s2"><title>关键词</title><p>重组人血小板生成素，移植相关血小板减少，造血干细胞移植</p></sec><sec id="s3"><title>Progress in the Application of Recombinant Human Thrombopoietin in Hematopoietic Stem Cell<sup> </sup></title><p>Yue Xu<sup>1</sup>, Peng Liu<sup>1</sup>, Yanli Wang<sup>2</sup>, Li Li<sup>2</sup>, Guitao Jie<sup>2*</sup></p><p><sup>1</sup>Weifang Medical University, Weifang Shandong</p><p><sup>2</sup>Department of Hematology, Linyi Central Hospital, Linyi Shandong</p><p><img src="//html.hanspub.org/file/56-1572339x5_hanspub.png" /></p><p>Received: May 21<sup>st</sup>, 2021; accepted: Jun. 9<sup>th</sup>, 2021; published: Jun. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/56-1572339x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Transplant-associated thrombocytopenia is one of the common complications after transplantation, which has complicated etiology and doesn't have definite treatment. Recombinant human thrombopoietin plays an important role in both the mobilization stage before transplantation and the post-transplantation stage, improving the occurrence of transplant-related thrombocytopenia and reducing the transfusion of platelets. At the same time, it shows good safety. The application of recombinant human thrombopoietin before and after transplantation is reviewed in this paper.</p><p>Keywords:Recombinant Human Thrombopoietin, Transplant-Associated Thrombocytopenia, Hemopoietic Stem Cell Transplantation</p><disp-formula id="hanspub.43449-formula55"><graphic xlink:href="//html.hanspub.org/file/56-1572339x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/56-1572339x8_hanspub.png" /> <img src="//html.hanspub.org/file/56-1572339x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>造血干细胞移植(hemopoietic stem cell transplantation, HSCT)是将采集的造血干细胞回输到患者体内重建造血及免疫功能的一种治疗手段，目前已广泛应用于恶性血液系统疾病和部分实体肿瘤的治疗。造血干细胞移植期间血小板减少是移植过程中常见的并发症之一，可见于移植的每个环节，其病因复杂，常提示预后差 [<xref ref-type="bibr" rid="hanspub.43449-ref1">1</xref>]。重组人血小板生成素(recombinant human thrombopoietin, rhTPO)可以提高造血干细胞动员产量 [<xref ref-type="bibr" rid="hanspub.43449-ref2">2</xref>] 和血小板数量 [<xref ref-type="bibr" rid="hanspub.43449-ref3">3</xref>]，在移植前动员阶段和移植后血小板重建阶段的运用都有效降低了移植相关血小板减少的发生。本文也将从这两个方面对重组人血小板生成素在造血干细胞移植中的应用做一综述。</p></sec><sec id="s6"><title>2. 重组人血小板生成素药理作用及作用机制</title><p>重组人血小板生成素(rhTPO)是利用基因重组技术，从中国仓鼠的卵巢细胞提纯后制成的完全糖基化人血小板生成素(TPO)重组蛋白。它与内源性血小板生成素(TPO)的氨基酸序列相同，其药理作用和作用机制也相似。</p><p>TPO主要作用在巨核细胞生成发育的整个过程，受血小板数量的调控，是巨核细胞增殖、分化、成熟以及血小板产生的重要调控因子 [<xref ref-type="bibr" rid="hanspub.43449-ref4">4</xref>]。TPO通过和C-mpl (重组人血小板生成素受体)特异性结合，刺激细胞质激酶来激活不同的信号通路，例如JAK-STAT途径，维持细胞活性，促进细胞增殖 [<xref ref-type="bibr" rid="hanspub.43449-ref5">5</xref>]；MAP激酶促进细胞成熟及PIK-AKT途径抑制细胞凋亡 [<xref ref-type="bibr" rid="hanspub.43449-ref6">6</xref>] 等，调控血小板生成。C-mpl是TPO唯一功能性的受体，在C-mpl转基因小鼠试验中，TPO与C-mpl特异性结合后促使造血干细胞和巨核细胞的增殖和分化的同时，清除了多余的TPO，使血小板的生成处在一个动态平衡状态 [<xref ref-type="bibr" rid="hanspub.43449-ref7">7</xref>]。</p><p>此外，重组人血小板生成素还可以直接作用于骨髓造血干细胞。相关动物模型在敲除TPO或TPO受体后，巨核系祖细胞数目减少到正常值的5%，虽然红细胞和白细胞的数目并没有受到影响，但红系和髓系祖细胞也减低到了正常值的40% [<xref ref-type="bibr" rid="hanspub.43449-ref8">8</xref>]。对暴露于全身照射(TBI)的小鼠和猕猴，照射后2 h单次给药rhTPO可显著减轻TBI诱导的小鼠死亡，其结果表明rhTPO促进多系造血恢复，增加外周血细胞计数、骨髓细胞数量和BM集落形成能力。同时，rhTPO处理小鼠的造血干细胞显示出多系重建增强，显著提高了骨髓移植后辐照的造血干细胞的移植能力 [<xref ref-type="bibr" rid="hanspub.43449-ref9">9</xref>]。</p><p>我国目前批准了重组人血小板生成素用于实体瘤化疗后的血小板减少(PLT ≤ 50 &#215; 10<sup>9</sup>/L)、糖皮质激素治疗无效且PLT ≤ 20 &#215; 10<sup>9</sup>/L的原发免疫性血小板减少症的辅助治疗 [<xref ref-type="bibr" rid="hanspub.43449-ref10">10</xref>]，以及重度再生障碍性贫血患者免疫治疗后促血小板生成 [<xref ref-type="bibr" rid="hanspub.43449-ref11">11</xref>] 等。</p></sec><sec id="s7"><title>3. 造血干细胞移植相关血小板减少相关进展</title><p>移植期间血小板减少主要发生在前期预处理时和移植后两个时期。移植前的预处理尤其是以清除肿瘤细胞为目的的清髓性方案 [<xref ref-type="bibr" rid="hanspub.43449-ref12">12</xref>]，可以使骨髓和巨核细胞受到抑制，本文不再详细说明。移植相关血小板减少是移植物功能不良最常见的临床表现，可分为原发性和继发性 [<xref ref-type="bibr" rid="hanspub.43449-ref13">13</xref>]。</p><sec id="s7_1"><title>3.1. 移植相关血小板减少常见原因</title><p>移植相关血小板减少与多种原因有关。造血干细胞动员不良时CD34<sup>+</sup>细胞输注量少，导致原发性移植物功能不良，主要表现为血小板重建延迟。移植物抗宿主病(graft versus host disease, GVHD) [<xref ref-type="bibr" rid="hanspub.43449-ref14">14</xref>]、巨细胞病毒感染、移植相关血栓性微血管病(TA-TMA)等因素 [<xref ref-type="bibr" rid="hanspub.43449-ref15">15</xref>] 均可以使血小板的破坏增加，导致继发性血小板减少。除此之外，供者对继发性血小板减少也有一定影响。供体特异性抗体(donor specific antiboby, DSA)阳性 [<xref ref-type="bibr" rid="hanspub.43449-ref16">16</xref>] 以及接受HLA全相合非同胞比同胞供者移植物的患者更易发生血小板减少 [<xref ref-type="bibr" rid="hanspub.43449-ref17">17</xref>]。</p></sec><sec id="s7_2"><title>3.2. 移植相关血小板减少发病机制</title><p>移植相关血小板减少的具体发病机制尚不明确，如血小板产生减少、血小板破坏增多、造血微环境异常等 [<xref ref-type="bibr" rid="hanspub.43449-ref18">18</xref>] 都可以导致其发生。相关研究发现 [<xref ref-type="bibr" rid="hanspub.43449-ref19">19</xref>]，血小板减少患者外周血中表达GPIIb-IIIa抗体的B细胞数增加，该细胞与血小板计数(BPC)呈负相关。造血微环境对巨核细胞的成熟、分化及干细胞的定植都发挥作用 [<xref ref-type="bibr" rid="hanspub.43449-ref20">20</xref>]。骨髓微环境异常可以使巨核细胞倍体分布核左移，导致血小板成熟障碍，血小板减少。最新研究发现移植后亦可发生免疫介导的血小板减少，通常认为是由于供者造血细胞(即功能失调的调节性T细胞)重建时免疫失调造成的 [<xref ref-type="bibr" rid="hanspub.43449-ref21">21</xref>]。</p></sec></sec><sec id="s8"><title>4. 重组人血小板生成素在造血干细胞移植中的临床应用</title><p>2021年4月我国相关血液学专家制定的《造血干细胞移植后出血并发症管理中国专家共识》指出，对于移植后血小板减少推荐血小板输注与重组人血小板生成素 [<xref ref-type="bibr" rid="hanspub.43449-ref15">15</xref>]。其中反复输注成分血小板支持治疗使输血相关性病毒感染发生率上升，血小板抗体发生率增加，导致无效输血；同时，增加血制品的用量，提高了住院次数和住院费用 [<xref ref-type="bibr" rid="hanspub.43449-ref22">22</xref>]。如何安全有效地降低移植相关血小板减少的发生及有效治疗血小板减少是临床上亟需解决的问题。</p><sec id="s8_1"><title>4.1. 移植前rhTPO的应用</title><p>自体外周血造血干细胞移植因其采集简单易行、造血及免疫过程恢复较快等特点被广泛应用于多发性骨髓瘤和淋巴瘤 [<xref ref-type="bibr" rid="hanspub.43449-ref23">23</xref>] 的患者。自体外周血造血干细胞移植除了移植后巨细胞病毒感染导致的继发性血小板减少外，最常见的原因是由于造血干细胞CD34<sup>+</sup>细胞输注量不足所导致的血小板重建延迟。移植物植入及造血重建的成功很大程度上与移植时CD34<sup>+</sup>细胞输注量有关。多中心将外周血造血干细胞动员的最低目标值定义为在4天或更短的时间内CD34<sup>+</sup>细胞的采集量 ≥ 2.0 &#215; 10<sup>6</sup>/kg [<xref ref-type="bibr" rid="hanspub.43449-ref24">24</xref>]。我国2017年中华骨髓库颁布的《造血干细胞移植技术管理规范(2017版)》要求干细胞收集量的标准为外周血单个核细胞(MNC)的采集量 ≥ 5.0 &#215; 10<sup>8</sup>/kg；在骨髓中单个核细胞(MNC)的采集量 ≥ 3.0 &#215; 10<sup>8</sup>/kg [<xref ref-type="bibr" rid="hanspub.43449-ref25">25</xref>]。目前我国常用的动员方案包括单用细胞因子、化疗联合细胞因子及含趋化因子受体CXCR4拮抗剂的新型动员剂，例如，普乐沙福等 [<xref ref-type="bibr" rid="hanspub.43449-ref26">26</xref>]。动员不良或是动员失败，不仅使患者错过了最佳的移植时机，而且增加了医疗资源消耗和医疗费用的支出。正如上文所述，重组人血小板生成素能提高造血干祖细胞数量，可以应用于移植前造血干细胞的动员阶段，特别是多发性骨髓瘤和淋巴瘤患者的移植动员 [<xref ref-type="bibr" rid="hanspub.43449-ref27">27</xref>]。</p><p>王椿等 [<xref ref-type="bibr" rid="hanspub.43449-ref28">28</xref>] 进行了一项多中心临床试验来评价使用血小板生成素联合化疗+G-CSF的动员方案治疗复发/难治性非霍奇金淋巴瘤，将78例一线治疗失败复发/难治的非霍奇金淋巴瘤患者在接受化疗后随机分成两组，结果显示TPO组CD34<sup>+</sup>细胞采集总数的中位数明显高于对照组CD34<sup>+</sup>细胞采集总数的中位数(6.35 &#215; 10<sup>6</sup>/kg vs 3.3 &#215; 10<sup>6</sup>/kg, P = 0.0054)；同时，动员时达CD34<sup>+</sup>细胞最低目标数的比率增高(100% vs 86%, P = 0.035)。该研究发现，rhTPO在复发/难治的非霍奇金淋巴瘤患者的使用中CD34<sup>+</sup>细胞细胞产量增加近50%，是一种有效的动员增强剂。王国蓉等 [<xref ref-type="bibr" rid="hanspub.43449-ref2">2</xref>] 在一项队列研究中对142名多发性骨髓瘤患者随机分成两组，其基线特征大致相同，研究结果显示，TPO组的成功率和理想率的优势比分别是91.7%和55.6%，明显高于非TPO组的55.6%和25.7%。总的来说，使用rhTPO联合中剂量CTX和G-CSF动员可以获得更高的干细胞产量。上述研究表明，rhTPO的使用可以提高CD34<sup>+</sup>细胞，同时，也提升了动员的成功率。</p></sec><sec id="s8_2"><title>4.2. 移植后rhTPO的应用</title><p>造血干细胞移植后异基因造血干细胞移植比自体造血干细胞移植，血小板减少的病因更常见、更复杂。移植后3个月或是更长时间内只发生血小板一系血细胞数量的减少，可称作持续孤立性血小板减少症(prolonged isolated thrombocytopenia, PT)，其发病率达9%~22.8% [<xref ref-type="bibr" rid="hanspub.43449-ref14">14</xref>]。有研究发现PT患者体内的内源性血小板生成素下降，这也可能是这类患者对重组人血小板生成素有效的原因所在 [<xref ref-type="bibr" rid="hanspub.43449-ref29">29</xref>]。重组人血小板生成素在异基因移植过程中不仅促进血小板的生长，减少输血治疗，同时也表现出良好的安全性 [<xref ref-type="bibr" rid="hanspub.43449-ref30">30</xref>]。</p><p>重组人血小板生成素在预防移植相关血小板减少方面有一定的疗效。江岷 [<xref ref-type="bibr" rid="hanspub.43449-ref31">31</xref>] 等对123例接受异基因造血干细胞移植的患者进行随机、对照试验。实验结果记录移植后第3~8周血小板的动态变化过程，发现试验组血小板植入时间明显快于对照组(P = 0.008)，同时缩短了血小板能达到100 &#215; 10<sup>9</sup>/L的时间。移植后成分血小板输注需求有所下降。美国FDA由于重组人血小板生成素抗TPO中和现象不再对其进行相关研究，但此次实验患者不良事件的发生率并没有统计学意义，表现出良好的移植安全性。脐血移植的患者由于干细胞的输注量少，移植后血小板的重建时间长，血小板减少的发生率高，成分输血的需求量上升。Baolin Tang [<xref ref-type="bibr" rid="hanspub.43449-ref32">32</xref>] 等就重组人血小板生成素促进脐血移植后血小板植入进行研究。将120名进行脐血移植的患者随机分成2组，TPO组在血小板植入后不再运用或是28天时停用，对照组不用rhTPO。其结果表明60天及120天时统计血小板植入率TPO组均比对照组高(83.1% vs 66.7%, P = 0.020; 81.4% vs 65.0%, P = 0.032)，成分输注血小板的需求量减少，两组均无发生严重的不良事件。</p><p>重组人血小板生成素在治疗移植相关血小板减少方面有一定的效果。吴德沛 [<xref ref-type="bibr" rid="hanspub.43449-ref33">33</xref>] 等对275例异基因造血干细胞移植的患者进行单中心回顾性研究。在本次实验中经多因素分析，移植相关血小板减少多发生在男性患者(P = 0.024)、造血干细胞即CD34+细胞输注量少(P = 0.04)及未使用rhTPO (P &lt; 0.001)的患者中。同时，对于骨髓增生异常综合征和再生障碍性贫血的患者，rhTPO组生存率较对照组上升(P = 0.014)。Sun YQ [<xref ref-type="bibr" rid="hanspub.43449-ref34">34</xref>] 等人将异基因移植后24例PT患者(包括延迟血小板植入和血小板恢复继发失败)给予rhTPO治疗，结果为rhTPO的总有效率为45.8%，显著高于历史数据(12.2%, P &lt; 0.001)。其中的11例对rhTPO有反应的患者中，治疗后骨髓巨核细胞的中位数显著增加(10 vs 2; P = 0.036)。对于异基因移植后PT患者，尤其是骨髓中有巨核细胞的患者，rhTPO的应答率为45.8%。所有患者均完成了28天的治疗，无一例因不良反应而退出治疗。总的来说，rhTPO在移植后预防和治疗血小板减少时都表现出了一定的效果和安全性。</p></sec></sec><sec id="s9"><title>5. 小结</title><p>移植相关血小板减少原因复杂多变且治疗暂无统一的指南及相关专家共识，可以发生在移植的每个环节中，常提示患者预后不良。重组人血小板生成素无论是在移植前的动员阶段，还是移植后骨髓造血重建的过程中都可以发挥其相应作用，降低血小板减少的发生。总之，移植相关血小板减少仍是我们经常面临的移植并发症之一。促血小板生长因子的使用给这一问题带来了新的解决办法，有待于我们进一步研究。</p></sec><sec id="s10"><title>文章引用</title><p>许 玥,刘 鹏,王彦丽,李 丽,接贵涛. 重组人血小板生成素在造血干细胞移植中应用的研究进展Progress in the Application of Recombinant Human Thrombopoietin in Hematopoietic Stem Cell[J]. 临床医学进展, 2021, 11(06): 2851-2856. https://doi.org/10.12677/ACM.2021.116414</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43449-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Akahoshi, Y., Kanda, J., Gomyo, A., et al. (2016) Risk Factors and Impact of Secondary Failure of Platelet Recovery after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 22, 1678-1683.  
&lt;br&gt;https://doi.org/10.1016/j.bbmt.2016.06.003</mixed-citation></ref><ref id="hanspub.43449-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wang, G., Chen, W., Wu, Y., et al. (2017) Recombinant Human Thrombopoietin Improves the Efficacy of Intermediate-Dose Cyclophosphamide plus Granulocyte Colony-Stimulating Factor in Mobilizing Peripheral Blood Stem Cells in Patients with Multiple Myeloma: A Cohort Study. Medicine (Baltimore), 96, e9302.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000009302</mixed-citation></ref><ref id="hanspub.43449-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">刘一, 吕欣, 董振香. 重组人血小板生成素的药理作用及临床评价[J]. 中国新药杂志, 2008, 17(3): 254-258.  
&lt;br&gt;https://doi.org/10.3321/j.issn:1003-3734.2008.03.020</mixed-citation></ref><ref id="hanspub.43449-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">周兴芹, 常仁安. 重组人促血小板生成素对化疗所致血小板减少症的防治效果[J]. 中国民间疗法, 2021, 29(5): 96-97. &lt;br&gt;https://doi.org/10.19621/j.cnki.11-3555/r.2021.0539</mixed-citation></ref><ref id="hanspub.43449-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Qian, J., Cao, X., Shen, Q., et al. (2021) Thrombopoietin Promotes Cell Proliferation and Attenuates Apoptosis of Aplastic Anemia Serum-Treated 32D Cells via Activating STAT3/STAT5 Signaling Pathway and Modulating Apoptosis-Related Mediators. Cell Transplant, 30. &lt;br&gt;https://doi.org/10.1177/0963689720980367</mixed-citation></ref><ref id="hanspub.43449-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mahat, U., Rotz, S.J., Hanna, R., et al. (2019) Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 26, e65-e73.  
&lt;br&gt;https://doi.org/10.1016/j.bbmt.2019.12.003</mixed-citation></ref><ref id="hanspub.43449-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Alexander, W.S. (1999) Thrombopoietin and the c-Mpl Receptor: Insights from Gene Targeting. The International Journal of Biochemistry &amp; Cell Biology, 31, 1027-1035. &lt;br&gt;https://doi.org/10.1016/S1357-2725(99)00079-5</mixed-citation></ref><ref id="hanspub.43449-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kuter, D.J. (2014) Milestones in Understanding Platelet Production: A Historical Overview. British Journal of Haematology, 165, 248-258. &lt;br&gt;https://doi.org/10.1111/bjh.12781</mixed-citation></ref><ref id="hanspub.43449-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Xing, S., Shen, X., Yang, J.K., et al. (2020) Single-Dose Administration of Recombinant Human Thrombopoietin Mitigates Total Body Irradiation-Induced Hematopoietic System Injury in Mice and Nonhuman Primates. International Journal of Radiation Oncology, Biology, Physics, 108, 1357-1367. &lt;br&gt;https://doi.org/10.1016/j.ijrobp.2020.07.2325</mixed-citation></ref><ref id="hanspub.43449-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">李虹. 重组人血小板生成素的药理作用[J]. 新医学导刊, 2008, 7(5): 12-13.</mixed-citation></ref><ref id="hanspub.43449-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Dong, Q., Fu, R., et al. (2015) Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy. BioMed Research International, 2015, Article ID: 597293. &lt;br&gt;https://doi.org/10.1155/2015/597293</mixed-citation></ref><ref id="hanspub.43449-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王茜茜, 姜尔烈, 韩明哲. 造血干细胞移植预处理方案的研究进展[J]. 国际输血及血液学杂志, 2017, 40(6): 533-538. &lt;br&gt;https://doi.org/10.3760/cma.j.issn.1673-419X.2017.06.013</mixed-citation></ref><ref id="hanspub.43449-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">黄爱杰, 胡晓霞, 王健民. 异基因造血干细胞移植术后血小板减少研究进展[J]. 中国实验血液学杂志, 2017, 25(1): 270-275.</mixed-citation></ref><ref id="hanspub.43449-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Akahoshi, Y., Kimura, S., Gomyo, A., et al. (2018) Delayed Platelet Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: Association with Chronic Graft-versus-Host Disease and Survival Outcome. Hematological Oncology, 36, 276-284. &lt;br&gt;https://doi.org/10.1016/j.ijrobp.2020.07.2325</mixed-citation></ref><ref id="hanspub.43449-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会血液学分会. 造血干细胞移植后出血并发症管理中国专家共识(2021年版) [J]. 中华血液学杂志, 2021, 42(4): 276-280.</mixed-citation></ref><ref id="hanspub.43449-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, X., Zhao, X., Huo, M., et al. (2017) Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. Journal of Immunology Research, 2017, Article ID: 1043836. &lt;br&gt;https://doi.org/10.1155/2017/1043836</mixed-citation></ref><ref id="hanspub.43449-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Dominietto, A., Raiola, A.M., van Lint, M.T., et al. (2001) Factors Influencing Haematological Recovery after Allogeneic Haemopoietic Stem Cell Transplants: Graft-versus-Host Disease, Donor Type, Cytomegalovirus Infections and Cell Dose. British Journal of Haematology, 112, 219-227. &lt;br&gt;https://doi.org/10.1155/2017/1043836</mixed-citation></ref><ref id="hanspub.43449-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">刘福佳, 沈杨. 血液系统恶性疾病患者接受造血干细胞移植期间血小板减少相关新进展[J]. 国际输血及血液学杂志, 2020, 43(5): 383-390.</mixed-citation></ref><ref id="hanspub.43449-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X.H., Wang, Q.M., Zhang, J.M., et al. (2015) Desialylation Is Associated with Apoptosis and Phagocytosis of Platelets in Patients with Prolonged Isolated Thrombocytopenia after Allo-HSCT. Journal of Hematology &amp; Oncology, 8, 116. &lt;br&gt;https://doi.org/10.1186/s13045-015-0216-3</mixed-citation></ref><ref id="hanspub.43449-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kong, Y., Hu, Y., Zhang, X., et al. (2014) Association between an Impaired Bone Marrow Vascular Microenvironment and Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 20, 1190-1197. &lt;br&gt;https://doi.org/10.1016/j.bbmt.2014.04.015</mixed-citation></ref><ref id="hanspub.43449-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Baur, K., Buser, A.S., et al. (2021) Immune Cytopenia after Allogeneic Haematopoietic Stem-Cell Transplantation: Challenges, Approaches, and Future Directions. Haematology, 8, 229-239.  
&lt;br&gt;https://doi.org/10.1016/S2352-3026(20)30404-X</mixed-citation></ref><ref id="hanspub.43449-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chu, T., Tang, Y., Wang, H., et al. (2017) Efficacy of Recombinant Factor VIIIa for Severe Bleeding Complicated by Platelet Transfusion Refractoriness in Patients with Hematologic Malignancies. Thrombosis Research, 160, 14-18.  
&lt;br&gt;https://doi.org/10.1016/j.thromres.2017.10.015</mixed-citation></ref><ref id="hanspub.43449-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Smith, S.M. (2017) Impact of Double-Hit and Double-Expressor Phenotypes in Relapsed Aggressive B-Cell Lymphomas Treated with Autologous Hematopoietic Stem Cell Transplantation. Journal of Clinical Oncology, 35, 1-3.  
&lt;br&gt;https://doi.org/10.1200/JCO.2016.70.0625</mixed-citation></ref><ref id="hanspub.43449-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">陈欢, 刘开彦. 自体造血干细胞动员的研究进展[J]. 中华血液学杂志, 2019, 40(10): 884-888.  
&lt;br&gt;https://doi.org/10.3760/cma.j.issn.0253-2727.2019.10.021</mixed-citation></ref><ref id="hanspub.43449-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">中华骨髓库. 造血干细胞移植技术管理规范(2017版) [Z]. 2017-03-03.</mixed-citation></ref><ref id="hanspub.43449-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Tim, S., Andrew, B. and Timothy, P. (2021) P2 3-Year Observation Study of Plerixafor Use in New Zealan. BJS Open, 5, zrab032.001. &lt;br&gt;https://doi.org/10.1093/bjsopen/zrab032.001</mixed-citation></ref><ref id="hanspub.43449-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zahid, U., Akbar, F., Amaraneni, A., et al. (2017) A Review of Autologous Stem Cell Transplantation in Lymphoma. Current Hematologic Malignancy Reports, 12, 217-226. &lt;br&gt;https://doi.org/10.1007/s11899-017-0382-1</mixed-citation></ref><ref id="hanspub.43449-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, J., Hao, S.G., Hu, J., et al. (2019) rhTPO Combined with Chemotherapy and G-CSF for Autologous Peripheral Blood Stem Cells in Patients with Refractory/Relapsed Non-Hodgkin’s Lymphoma. Cancer Management and Research, 11, 8371-8377. &lt;br&gt;https://doi.org/10.2147/CMAR.S219242</mixed-citation></ref><ref id="hanspub.43449-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Fu, H., Xu, L., et al. (2011) Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with a Reduction in Ploidy and an Immaturation of Megakaryocytes. Biology of Blood and Marrow Transplantation, 17, 274-280. &lt;br&gt;https://doi.org/10.1016/j.bbmt.2010.09.007</mixed-citation></ref><ref id="hanspub.43449-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">宋媛, 周芳, 宋宁霞, 等. 重组人血小板生成素对重型再生障碍性贫血患者异基因造血干细胞移植后血小板恢复的影响[J]. 中华血液学杂志, 2018(3): 207-211. &lt;br&gt;https://doi.org/10.3760/cma.j.issn.0253-2727.2018.03.007</mixed-citation></ref><ref id="hanspub.43449-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">江岷, 潘欣, 徐晨, 等. 重组人血小板生成素促进异基因造血干细胞移植血小板恢复的随机对照临床试验[J]. 血栓与止血学, 2011, 17(6): 247-253. &lt;br&gt;https://doi.org/10.3969/j.issn.1009-6213.2011.06.002</mixed-citation></ref><ref id="hanspub.43449-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Tang, B., Huang, L., Liu, H., et al. (2020) Recombinant Human Thrombopoietin Promotes Platelet Engraftment after Umbilical Cord Blood Transplantation. Blood Advances, 4, 3829-3839.  
&lt;br&gt;https://doi.org/10.1182/bloodadvances.2020002257</mixed-citation></ref><ref id="hanspub.43449-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Huang, M., Zhao, Y., et al. (2017) Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 23, 1678-1684.  
&lt;br&gt;https://doi.org/10.1182/bloodadvances.2020002257</mixed-citation></ref><ref id="hanspub.43449-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Y.Q., Kong, Y., Zhang, X.H., et al. (2019) A Novel Recombinant Human Thrombopoietin for Treating Prolonged Isolated Thrombocytopenia after Allogeneic Stem Cell Transplantation. Platelets, 30, 994-1000.  
&lt;br&gt;https://doi.org/10.1080/09537104.2018.1557613</mixed-citation></ref></ref-list></back></article>